[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616566":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":28,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Syntis Bio","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Drug SYNT101","ACTIVE_COMPARATOR",null,[13],"Drug: SYNT101",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","SYNT101","Tablet",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"Placebo tablet to match SYNT101 in appearance.",[15],[29],{"facility":30,"status":31,"city":32,"state":33,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Veritus Research","RECRUITING","Bayswater","Victoria","Australia","AU",{"type":37,"coordinates":38},"Point",[39,40],145.26667,-37.85,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Rebecca Wolf","CONTACT","+61 3 8736 1750","info@veritusresearch.com",{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100616566","phase-1-a-study-of-synt-101-to-test-safety-tolerability-and-pharmacodynamics-of-synt-101-in-healthy-and-overweight-adults-100616566",false,"NCT07307274","A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults","A Phase 1 Randomised, Double-blind, Placebo-controlled Single Ascending and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYNT-101 in Healthy Adults and Healthy Adults Who Are Overweight or Have Obesity","Inclusion Criteria:\n\n* Must be able to understand the full nature and purpose of the study, including possible risks and adverse effects.\n* Adult males and females, 18 to 55 years of age (inclusive) at screening.\n* Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant (CS) abnormalities.\n* Have suitable venous access for blood sampling.\n* Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n\nExclusion Criteria:\n\n* Known hypersensitivity to the study drug or any of the study drug ingredients.\n* History of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer's ability to participate in the study.\n* History or presence of CS cardiovascular, pulmonary, hepatic, renal, haematological, endocrine, immunologic, dermatologic, psychiatric, or neurological disease\u002Fdisorder, including any acute illness, within the past 3 months determined by the PI (or delegate) to be clinically relevant.",true,"ALL","18 Years","55 Years",{"count":62,"type":63},64,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.",[69,70],"Healthy","Overweight and Obese Adults","2026-04-28",{"date":73,"type":74},"2026-04-29","ACTUAL",{"date":76,"type":74},"2026-01-13",{"date":78,"type":63},"2026-12-31",{"name":5,"class":6},1]